Lantheus Holdings Inc - Asset Resilience Ratio
Lantheus Holdings Inc (LNTH) has an Asset Resilience Ratio of -0.08% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LNTH current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2017)
This chart shows how Lantheus Holdings Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see LNTH total assets.
Liquid Assets Composition Over Time
This chart breaks down Lantheus Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore LNTH long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-1.66 Million | -0.08% |
| Total Liquid Assets | $-1.66 Million | -0.08% |
Asset Resilience Insights
- Limited Liquidity: Lantheus Holdings Inc maintains only -0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Lantheus Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Lantheus Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Annual Asset Resilience Ratio for Lantheus Holdings Inc (2013–2017)
The table below shows the annual Asset Resilience Ratio data for Lantheus Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.03% | $100.00K | $383.86 Million | -0.01pp |
| 2016-12-31 | 0.04% | $100.00K | $255.90 Million | 0.00pp |
| 2015-12-31 | 0.04% | $100.00K | $242.38 Million | -0.04pp |
| 2013-12-31 | 0.08% | $200.00K | $261.31 Million | -- |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more